Lonnie Pyne
@lonniepyne.bsky.social
π€ 914
π₯ 322
π 52
Nephrologist Assistant Professor McMaster University
Hi everyone. Lonnie Pyne, nephrologist from McMaster University in Hamilton, Ontario, Canada joining for
#NephJC
tonight. COI - one of the authors
2 months ago
3
14
3
reposted by
Lonnie Pyne
Michael Walsh
3 months ago
Following
#ACHIEVE
our meta-analysis of RCTs of MRAs for pts receiving dialysis in
@thelancet.com
. Thanks to
@lonniepyne.bsky.social
for leading. No signal for benefit among low-risk of bias RCTs and a good demo of why we continue to need large simple trials.
www.sciencedirect.com/science/arti...
loading . . .
Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials
Mineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but theβ¦
https://www.sciencedirect.com/science/article/pii/S0140673625011535?dgcid=author
0
13
4
reposted by
Lonnie Pyne
Michael Walsh
3 months ago
Proud to have worked with colleagues and friends around the world on
#ACHIEVE
. We're disappointed spiro didn't prevent CV death/heart failure hospitalizations, but we've shown it's possible to do publicly funded large RCTs of repurposed meds in ESKD. More to do!
www.sciencedirect.com/science/arti...
loading . . .
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial
Patients undergoing maintenance dialysis for kidney failure are at substantial risk of cardiovascular morbidity and mortality. We aimed to establish iβ¦
https://www.sciencedirect.com/science/article/pii/S0140673625011985?dgcid=author
0
12
3
you reached the end!!
feeds!
log in